The KDIGO clinical practice guideline for diabetes management in CKD recommends a layered approach built on lifestyle and first-line SGLT2 inhibitor and RAAS-inhibitor therapy, adding GLP-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists for additional heart and kidney protection.